Neurogene (NGNE) Preferred Stock Liabilities (2013 - 2022)
Neurogene's (NGNE) quarterly Preferred Stock Liabilities came in at $244.4 million in Q4 2022, up 230.86% on a QoQ basis from $73.9 million in Q4 2013.
Powered by 
Analysis
Neurogene (NGNE) Preferred Stock Liabilities (2013 - 2022) Analysis & Trends
Neurogene (NGNE) has 2 years of Preferred Stock Liabilities data on file, last reported at $244.4 million in Q4 2022.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $244.4 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $244.4 million (changed N/A YoY) and the FY2022 annual result came in at $244.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $244.4 million in Q4 2022, from $73.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $244.4 million in Q4 2022 to a low of $244.4 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 244.37 Mn |
| Dec 31, 2021 | 114.82 Mn |
| Mar 12, 2014 | 48.51 Mn |
| Dec 31, 2013 | 73.86 Mn |